Make your reservation for this case study-focused session starring the probability-weighted expected return method (PWERM). Using the backdrop of a clinical stage biotech company, you’ll observe the differences and similarities between the PWERM and the option pricing method. Join leading expert Annika Reinemann, who will lead a discussion of PWERM when challenged with several potential solutions. Whether you’re performing calculations with weighted average discount rates, underfunded cash flows, or the inclusion of future rounds, this session will help you confidently power through your next valuation using the PWERM.